Compass Therapeutics to Present Second Quarter Financial Results and Provide Business Update on August 11, 2025
Compass Therapeutics (NASDAQ: CMPX), a clinical-stage oncology biopharmaceutical company, will host its Q2 2025 financial results conference call on August 11, 2025, at 8:00 AM ET. The presentation will include updates on multiple programs including the tovecimig Phase 2/3 study, clinical data for CTX-8371, and preclinical data for CTX-10726.
Investors can access the webcast via the provided link or join by phone using the dial-in numbers. A replay will be available for 90 days on Compass' Events page.
Compass Therapeutics (NASDAQ: CMPX), una società biofarmaceutica oncologica in fase clinica, terrà la conference call sui risultati finanziari del secondo trimestre 2025 il 11 agosto 2025 alle 8:00 ET. La presentazione includerà aggiornamenti su più programmi, incluso lo studio di fase 2/3 di tovecimig, i dati clinici di CTX-8371 e i dati preclinici di CTX-10726.
Gli investitori potranno seguire il webcast tramite il link fornito o partecipare telefonicamente usando i numeri di accesso. Una registrazione sarà disponibile per 90 giorni nella pagina Eventi di Compass.
Compass Therapeutics (NASDAQ: CMPX), una compañía biofarmacéutica oncológica en fase clínica, celebrará su conferencia telefónica sobre resultados financieros del 2T 2025 el 11 de agosto de 2025 a las 8:00 ET. La presentación incluirá actualizaciones de varios programas, incluido el estudio de fase 2/3 de tovecimig, los datos clínicos de CTX-8371 y los datos preclínicos de CTX-10726.
Los inversores podrán acceder al webcast mediante el enlace proporcionado o unirse por teléfono usando los números de marcación. Una grabación estará disponible durante 90 días en la página de Eventos de Compass.
Compass Therapeutics (NASDAQ: CMPX)는 임상 단계의 종양학 바이오제약 회사로, 2025년 2분기 실적 콘퍼런스 콜을 2025년 8월 11일 오전 8시(ET)에 개최합니다. 발표에서는 tovecimig의 2/3상(Phase 2/3) 연구, CTX-8371의 임상 데이터, CTX-10726의 전임상 데이터 등 여러 프로그램에 대한 업데이트가 포함됩니다.
투자자들은 제공된 링크를 통해 웹캐스트에 접속하거나 전화 접속 번호로 참여할 수 있습니다. 콘퍼런스 콜 녹음은 Compass의 이벤트 페이지에서 90일 동안 다시보기로 제공됩니다.
Compass Therapeutics (NASDAQ: CMPX), une société biopharmaceutique oncologique en phase clinique, tiendra sa conférence téléphonique sur les résultats financiers du T2 2025 le 11 août 2025 à 8h00 (ET). La présentation comprendra des mises à jour sur plusieurs programmes, y compris l’étude de phase 2/3 de tovecimig, les données cliniques de CTX‑8371 et les données précliniques de CTX‑10726.
Les investisseurs pourront accéder au webinaire via le lien fourni ou se joindre par téléphone en utilisant les numéros d’accès. Une rediffusion sera disponible pendant 90 jours sur la page Événements de Compass.
Compass Therapeutics (NASDAQ: CMPX), ein klinisch tätiges onkologisches Biopharmaunternehmen, wird seine Telefonkonferenz zu den Finanzergebnissen für das zweite Quartal 2025 am 11. August 2025 um 8:00 Uhr ET abhalten. Die Präsentation enthält Updates zu mehreren Programmen, darunter die Phase‑2/3‑Studie zu tovecimig, die klinischen Daten zu CTX‑8371 und die präklinischen Daten zu CTX‑10726.
Investoren können das Webcast über den bereitgestellten Link verfolgen oder sich telefonisch über die Einwahlnummern zuschalten. Eine Aufzeichnung wird für 90 Tage auf der Eventseite von Compass verfügbar sein.
- None.
- None.
BOSTON, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics, will release its financial results for the quarter ended June 30, 2025 and host a webcast and conference call to provide an update on the ongoing tovecimig Phase 2/3 study, clinical data for CTX-8371 and preclinical data for CTX-10726, on Monday, August 11, 2025, at 8:00 a.m. ET.
Call Details:
Date: Monday, August 11, 2025
Time: 8:00 AM ET
Webcast: https://viavid.webcasts.com/starthere.jsp?ei=1727543&tp_key=955a2c2f4d
Dial-In: 1-877-407-9716 (US), 1-201-493-6779 (International), 13754954 (Conference ID)
Virtual/Replay availability: A replay will be archived for 90 days on Compass’ Events page.
About Compass Therapeutics
Compass Therapeutics, Inc. is a clinical-stage oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company’s scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. Compass has built a robust pipeline of novel product candidates designed to target multiple critical biological pathways required for an effective anti-tumor response. These include modulation of the microvasculature via angiogenesis-targeted agents, induction of a potent immune response via activators on effector cells in the tumor microenvironment, and alleviation of immunosuppressive mechanisms used by tumors to evade immune surveillance. The company plans to advance its product candidates through clinical development as both standalone therapies and in combination with proprietary pipeline antibodies based on supportive clinical and nonclinical data. The Company was founded in 2014 and is headquartered in Boston, Massachusetts. For more information, visit the Compass Therapeutics website at https://www.compasstherapeutics.com.
Investor Contact
ir@compasstherapeutics.com
Media Contact
Anna Gifford, Chief of Staff
media@compasstherapeutics.com
617-500-8099
FAQ
When will Compass Therapeutics (CMPX) report Q2 2025 earnings?
What will be discussed in Compass Therapeutics' Q2 2025 earnings call?
How can investors access Compass Therapeutics' Q2 2025 earnings call?
How long will the replay of Compass Therapeutics' Q2 earnings call be available?
